×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Molecular Predictors of Drug-induced Harm: From Clinical Development to Postmarketing Surveillance
Session Chair(s)
Niklas Noren, PhD, MSc
Chief Science Officer
Uppsala Monitoring Centre (UMC) , Sweden
Drug-Drug Interactions: Current Regulatory Perspectives and Clinical Relevance
Learning Objective : Identify the relevance and application of drug interaction predictive models to clinical development; Describe the opportunities and challenges presented by molecular-based analyses of drug-induced harm from postmarketing surveillance data.
Speaker(s)
Drug-Drug Interactions: Current Regulatory Perspectives and Clinical Relevance
Peter J. Kilford, PhD
Covance Inc. , United Kingdom
Senior Project Manager
Molecular Analysis of Patient Adverse Events
Niels Christian Bojunga, PhD
Molecular Health GmbH, Germany
Head of Quality Assurance
Chemical Structure in Pharmacovigilance: Molecular Predictors of Drug-induced Harm
Niklas Noren, PhD, MSc
Uppsala Monitoring Centre (UMC) , Sweden
Chief Science Officer
Have an account?